Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Aiming to Reach Millions of Mental Health Patients with Effective, Affordable Ketamine Treatments
- Mental health conditions affect millions of people globally, some of whom are resistant to existing treatments
- In the early 1990s, Yale researchers discovered that ketamine offered immediate relief to chronically depressed patients, and since then, the scientists have continually investigated the compound’s role in mental health treatment
- Delic’s subsidiary, Ketamine Wellness Centers, notes that ketamine is now extensively used for multiple treatment-resistant mental conditions, with patient outcomes showing its therapeutic effectiveness
- Delic hopes to reach millions of people suffering from various mental health conditions who have lost hope of finding effective, affordable treatments
The World Health Organization (“WHO”) reports that mental health conditions, including depression, bipolar disorder, anxiety, schizophrenia, dementia, developmental disorders, post-traumatic stress disorder (“PTSD”), and more, are on the rise worldwide. Data from the ten years to 2017 showed a 13% increase in mental health conditions and substance use disorders, with the former causing disability among patients – for one in five years (https://nnw.fm/XmiGY). A 2017 study estimated that about 10.7% of the world population, or 792 million people, lived with a mental health disorder (https://nnw.fm/ahGTY).
More specifically, depression, a common illness worldwide that affected 264 million people in 2017, currently affects about 280 million people globally. Anxiety disorders and bipolar disorder affected 284 million people and 46 million people, respectively, in 2017. Cumulatively, 970 million people had a mental or substance use disorder.
Mental health conditions impact every sphere of patients’ lives, including school, work, personal relationships, and the ability to engage in social activities. And keeping in mind that some patients are resistant to existing treatments, the burden is compounded even further. Combined, depression and anxiety, the two most common mental illnesses, usurp US$1 trillion annually from the global economy. So, the developments ensuing from an early 1990s observation by Yale scientists that pediatric anesthetic ketamine offered immediate relief to chronically depressed patients provide much-needed reprieve.
Since the discovery, Yale researchers have continually investigated ketamine’s role in mental health treatments. “In their research, [the Elizabeth Mears and House Jameson Professor of Psychiatry and Professor of Neurobiology Ronald] Duman and others show that in a series of steps, ketamine triggers release of neurotransmitter glutamate, which in turn stimulates growth of synapses. Research at Yale has shown that damage of these synaptic connections caused by chronic stress is rapidly reversed by a single dose of ketamine,” a 2012 Yale News article reads (https://nnw.fm/1Quhx).
Building on the years of research into the use of ketamine as a treatment for depression, Yale scientists began investigating whether this compound could help patients suffering from severe PTSD. And according to Ketamine Wellness Centers (“KWC”), a wholly owned subsidiary of Delic Holdings (CSE: DELC) (OTCQB: DELCF), ketamine is now extensively utilized for treatment-resistant depression, anxiety, PTSD, suicidality, obsessive-compulsive disorder (“OCD”), PTSD, chronic and neuropathic pain, and anxious bipolar depression.
Data provided by KWC, in fact, demonstrate that ketamine treatment has shown effectiveness of more than 50% among patients with borderline personality disorder, over 65% effectiveness in patients with depression and PTSD or anxiety, more than 76% effectiveness in patients with major depressive disorders, and over 80% effectiveness in patients with bipolar disorder (data available via Delic’s January 2022 investor deck at (https://nnw.fm/BAJqr).
These successful outcomes are due to a carefully designed treatment approach wherein KWC’s skilled professionals with experience in ketamine therapy administer clinically controlled protocols to patients in therapeutic settings and offer medical supervision (https://nnw.fm/2cN0R).
Through KWC, Delic operates the largest, profitable chain of wellness clinics in the United States with 13 clinics across nine states with plans to open more state-of-the-art clinics in the ensuing 18 months.
“We are thrilled to officially welcome the KWC team to the Delic family and cement our place as the largest network of treatment clinics in the U.S. With the addition of KWC, we can now reach millions of people suffering from various mental health conditions who have lost hope of finding effective, affordable treatments,” commented Delic Co-founder and CEO Matt Stang in a November 9 news release announcing the acquisition of KWC (https://nnw.fm/e8PPJ).
For more information, visit the company’s website at www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://nnw.fm/DELCF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Mental health conditions affect millions of people globally, some of whom are resistant to existing treatments
- In the early 1990s, Yale researchers discovered that ketamine offered immediate relief to chronically depressed patients, and since then, the scientists have continually investigated the compound’s role in mental health treatment
- Delic’s subsidiary, Ketamine Wellness Centers, notes that ketamine is now extensively used for multiple treatment-resistant mental conditions, with patient outcomes showing its therapeutic effectiveness
- Delic hopes to reach millions of people suffering from various mental health conditions who have lost hope of finding effective, affordable treatments
The World Health Organization (“WHO”) reports that mental health conditions, including depression, bipolar disorder, anxiety, schizophrenia, dementia, developmental disorders, post-traumatic stress disorder (“PTSD”), and more, are on the rise worldwide. Data from the ten years to 2017 showed a 13% increase in mental health conditions and substance use disorders, with the former causing disability among patients – for one in five years (https://nnw.fm/XmiGY). A 2017 study estimated that about 10.7% of the world population, or 792 million people, lived with a mental health disorder (https://nnw.fm/ahGTY).
More specifically, depression, a common illness worldwide that affected 264 million people in 2017, currently affects about 280 million people globally. Anxiety disorders and bipolar disorder affected 284 million people and 46 million people, respectively, in 2017. Cumulatively, 970 million people had a mental or substance use disorder.
Mental health conditions impact every sphere of patients’ lives, including school, work, personal relationships, and the ability to engage in social activities. And keeping in mind that some patients are resistant to existing treatments, the burden is compounded even further. Combined, depression and anxiety, the two most common mental illnesses, usurp US$1 trillion annually from the global economy. So, the developments ensuing from an early 1990s observation by Yale scientists that pediatric anesthetic ketamine offered immediate relief to chronically depressed patients provide much-needed reprieve.
Since the discovery, Yale researchers have continually investigated ketamine’s role in mental health treatments. “In their research, [the Elizabeth Mears and House Jameson Professor of Psychiatry and Professor of Neurobiology Ronald] Duman and others show that in a series of steps, ketamine triggers release of neurotransmitter glutamate, which in turn stimulates growth of synapses. Research at Yale has shown that damage of these synaptic connections caused by chronic stress is rapidly reversed by a single dose of ketamine,” a 2012 Yale News article reads (https://nnw.fm/1Quhx).
Building on the years of research into the use of ketamine as a treatment for depression, Yale scientists began investigating whether this compound could help patients suffering from severe PTSD. And according to Ketamine Wellness Centers (“KWC”), a wholly owned subsidiary of Delic Holdings (CSE: DELC) (OTCQB: DELCF), ketamine is now extensively utilized for treatment-resistant depression, anxiety, PTSD, suicidality, obsessive-compulsive disorder (“OCD”), PTSD, chronic and neuropathic pain, and anxious bipolar depression.
Data provided by KWC, in fact, demonstrate that ketamine treatment has shown effectiveness of more than 50% among patients with borderline personality disorder, over 65% effectiveness in patients with depression and PTSD or anxiety, more than 76% effectiveness in patients with major depressive disorders, and over 80% effectiveness in patients with bipolar disorder (data available via Delic’s January 2022 investor deck at (https://nnw.fm/BAJqr).
These successful outcomes are due to a carefully designed treatment approach wherein KWC’s skilled professionals with experience in ketamine therapy administer clinically controlled protocols to patients in therapeutic settings and offer medical supervision (https://nnw.fm/2cN0R).
Through KWC, Delic operates the largest, profitable chain of wellness clinics in the United States with 13 clinics across nine states with plans to open more state-of-the-art clinics in the ensuing 18 months.
“We are thrilled to officially welcome the KWC team to the Delic family and cement our place as the largest network of treatment clinics in the U.S. With the addition of KWC, we can now reach millions of people suffering from various mental health conditions who have lost hope of finding effective, affordable treatments,” commented Delic Co-founder and CEO Matt Stang in a November 9 news release announcing the acquisition of KWC (https://nnw.fm/e8PPJ).
For more information, visit the company’s website at www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://nnw.fm/DELCF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
